Financial Data and Key Metrics Changes - Total revenue for the quarter was $789 million, with non-GAAP operating income of $353 million, exceeding guidance [6][7]. - The company expressed confidence in its $6 billion revenue plan over the next five years, indicating strong performance and growth potential [22]. Business Line Data and Key Metrics Changes - R&D subscriptions and services showed significant upside, indicating a broad-based growth across all areas [19][40]. - The resolution of the lawsuit with IQVIA is expected to enhance the commercial cloud offerings, particularly in integrating IQVIA data into Veeva's products [12][14]. Market Data and Key Metrics Changes - The company reported strong execution across its business segments, with no specific areas of weakness despite macroeconomic uncertainties [124]. - The commercial cloud segment is anticipated to benefit from the resolution with IQVIA, allowing for a more comprehensive solution for customers [73][86]. Company Strategy and Development Direction - Veeva is focusing on enhancing its AI capabilities, with plans to integrate AI agents into its existing platforms, which is expected to create significant value for the industry over time [28][30]. - The company aims to leverage its structural advantages in the life sciences sector to lead in industry-specific cloud applications and AI agents [46][48]. Management's Comments on Operating Environment and Future Outlook - Management noted that while there is elevated uncertainty in the macro environment, customer engagement remains strong, and the pipeline is building effectively [124]. - The company does not expect immediate revenue contributions from the IQVIA resolution but sees it as a long-term growth driver [90]. Other Important Information - The company is working on refining its migration tooling to facilitate customer transitions to the Vault CRM, with over 20 customers already migrated and 300 more planned [106]. - Veeva's business consulting services are seen as a critical component in driving AI adoption and helping customers navigate changes in workflows [111][115]. Q&A Session Summary Question: What led to the resolution of the lawsuit with IQVIA? - The resolution was driven by changes in the industry landscape and a mutual recognition that collaboration would benefit both companies and their customers [12][14]. Question: How does the resolution with IQVIA unlock new opportunities? - It removes previous barriers to integrating IQVIA data into Veeva's products, enhancing the commercial cloud offerings and allowing for more comprehensive solutions [14][73]. Question: What is the outlook for R&D subscription growth? - R&D subscriptions are expected to continue growing, supported by strong execution across all areas and a stable environment [40][76]. Question: How does Veeva plan to leverage AI in its offerings? - Veeva plans to integrate AI agents into its platforms, enhancing productivity and creating new revenue opportunities over time [28][30]. Question: What is the customer reaction to the IQVIA resolution? - Customer feedback has been overwhelmingly positive, as the resolution alleviates previous integration issues and opens up new possibilities for collaboration [34][36]. Question: What are the expectations for commercial subscriptions moving forward? - The company anticipates continued strength in commercial subscriptions, particularly driven by the Crossix product, despite some flatness in the recent quarter [74][76]. Question: How does Veeva differentiate itself in the AI space? - Veeva's structural advantage lies in its deep industry-specific applications, allowing for seamless integration of AI agents into existing workflows [94][96].

Financial Performance & Growth (FY2025 & FY2026 Guidance) - Total revenue for FY2025 reached $2.747 billion, with a year-over-year growth of 16%[8] - The company projects total revenue for FY2026 to be between $3.134 billion and $3.140 billion, indicating an anticipated growth of approximately 14%[8, 28] - Subscription revenue for FY2026 is guided at approximately $2.657 billion[28] - Non-GAAP operating income for FY2026 is projected to be around $1.388 billion, with a margin of approximately 44%[14, 28] - Normalized billings for FY2026 are expected to be approximately $3.355 billion, representing a year-over-year growth of about 13%[20, 28] - Non-GAAP cash from operations for FY2026 is guided at approximately $1.330 billion[24, 28] Q2'26 Results & Q3'26 Guidance - Total revenue for Q2'26 was $789.1 million, a 17% increase year-over-year[37] - Subscription revenue for Q2'26 was $659.2 million, reflecting a 17% year-over-year growth[37] - The company anticipates total revenue for Q3'26 to be between $790 million and $793 million[31] - Subscription revenue for Q3'26 is projected to be approximately $671 million[31] - Non-GAAP operating income for Q3'26 is expected to be between $348 million and $350 million[31] Additional Considerations - The company standardized termination for convenience (TFC) rights in customer contracts, which had a one-time impact on revenue and operating income in FY2024, but no impact after FY2025[48, 51]

"It's exciting to see our vision of connected software, data, and business consulting for life sciences becoming a reality," said CEO Peter Gassner. "I am especially excited about the power of Veeva AI and Veeva Data Cloud to enable transformational change for life sciences from clinical to commercial." Exhibit 99.1 FOR IMMEDIATE RELEASE Veeva Announces Fiscal 2026 Second Quarter Results Total Revenues of $789.1M, up 17% Year Over Year Subscription Services Revenues of $659.2M, up 17% Year Over Year PLEASAN ...

Core Viewpoint - Analysts expect Veeva Systems to report quarterly earnings of $1.90 per share, reflecting a year-over-year increase of 17.3%, with revenues projected at $767.61 million, up 13.5% from the previous year [1] Earnings Estimates - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [2] Revenue Projections - Analysts forecast 'Revenues- Subscription services' to reach $649.25 million, indicating a year-over-year change of +15.7% [4] - 'Revenues- Professional services and other' are expected to be $118.36 million, reflecting a +3% change from the prior year [4] - 'Revenues- Professional services and other- Veeva R&D Solutions' is projected to reach $72.75 million, with a year-over-year change of +4.2% [4] - 'Revenues- Subscription services- Veeva R&D Solutions' is estimated at $342.74 million, showing a year-over-year change of +18.4% [5] - 'Revenues- Subscription services- Veeva Commercial Solutions' is expected to be $306.25 million, indicating a +12.7% change from the previous year [5] - 'Revenues- Professional services and other- Veeva Commercial Solutions' is projected at $45.59 million, reflecting a +1.2% change from the prior year [6] Gross Margin Estimates - The 'Non-GAAP Gross Margin- Professional Services and other' is expected to be 29.7%, down from 31.9% year-over-year [6] - The average prediction for 'Non-GAAP Gross Margin- Subscription services' is 86.8%, slightly up from 86.5% year-over-year [7] Stock Performance - Veeva shares have decreased by -3.1% over the past month, contrasting with a +1.1% increase in the Zacks S&P 500 composite [7]

Core Insights - Veeva Systems is hosting the Veeva R&D and Quality Summit on September 3-4, 2025, in Boston, featuring leaders from major biopharmaceutical companies like BeOne Medicines, Intercept Pharmaceuticals, Merck, and Pfizer to discuss advancements in clinical, regulatory, safety, and quality processes [1][5] Group 1: Event Highlights - The summit will showcase over 100 sessions focused on the latest advancements in life sciences, including strategies for accelerating development and manufacturing by connecting systems and processes [3] - Key topics include improving trial oversight and collaboration among sites, sponsors, and CROs [4] Group 2: Innovations and Technologies - Veeva will highlight its advancements in software, data, and business consulting, particularly the integration of Veeva AI into the Vault Platform, which provides secure access to data and workflows [2] - The event will feature discussions on how customers can leverage Veeva AI to create custom agents tailored to their needs [2] Group 3: Industry Engagement - The summit aims to foster an environment of openness where industry leaders can share experiences and ideas to expedite the delivery of medicines to patients [5] - More than 2,000 attendees are expected, all of whom are life sciences professionals [6] Group 4: Company Overview - Veeva Systems is recognized as a global leader in cloud software for the life sciences industry, serving over 1,000 customers, including large biopharmaceutical companies and emerging biotechs [7]

Company Performance - Veeva Systems closed at $279.18, with a daily increase of +1.36%, outperforming the S&P 500's gain of 0.32% [1] - The stock has decreased by 1.39% over the past month, underperforming the Medical sector's loss of 2.75% and the S&P 500's gain of 3.08% [1] Upcoming Earnings - The upcoming earnings report is scheduled for August 27, 2025, with projected EPS of $1.9, reflecting a 17.28% increase year-over-year [2] - Revenue is anticipated to be $767.61 million, indicating a 13.52% increase compared to the same quarter last year [2] Full Year Estimates - For the full year, earnings are expected to be $7.64 per share, marking a +15.76% change from the previous year [3] - Revenue for the year is projected at $3.1 billion, representing a +12.78% increase from last year [3] Analyst Estimates - Changes in analyst estimates are crucial as they reflect short-term business trends, with positive revisions indicating optimism about the business outlook [4] - The Zacks Rank system, which evaluates these estimate changes, currently ranks Veeva Systems at 2 (Buy) [6] Valuation Metrics - Veeva Systems has a Forward P/E ratio of 36.03, which is a premium compared to the industry average of 22.73 [7] - The company has a PEG ratio of 1.55, which is lower than the Medical Info Systems industry's average PEG ratio of 2.83 [7] Industry Ranking - The Medical Info Systems industry ranks in the top 30% of all industries, with a Zacks Industry Rank of 72 [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - Veeva Systems Inc. (VEEV) is positioned for growth due to its strong product portfolio and solid first-quarter fiscal 2026 performance, despite concerns over rising operational costs [1][12]. Financial Performance - Veeva's shares have increased by 31.7% year-to-date, outperforming the industry growth of 19.9% and contrasting with the S&P 500's decline of 8.5% [2]. - The company has a market capitalization of $46.1 billion and anticipates a growth rate of 26.2% over the next five years, with a trailing four-quarter average earnings surprise of 10% [3]. Product and Service Developments - Veeva continues to drive the adoption of its next-gen Vault CRM, with 20 new customers, particularly from small and mid-sized biotech firms [5]. - The introduction of AI-driven innovations, such as CRM Voice Control and MLR Bot, aims to enhance efficiency and compliance [6]. - Veeva's Data Cloud solutions are gaining traction, with significant contracts and partnerships, including a long-term collaboration with Walgreens Boots Alliance [7][9]. Strategic Initiatives - The company has secured key deals, including Boehringer Ingelheim's migration to Veeva Vault CRM and partnerships to enhance generative AI capabilities [9]. - Veeva's first-quarter fiscal 2026 results exceeded expectations, driven by strong performance in subscription and professional services [10]. Cost Management - Operating costs have risen, with general and administrative expenses increasing by 12.3% year-over-year in the first quarter of fiscal 2026 [12]. - Total operating expenses increased by 9.4% year-over-year, with expectations for further increases due to employee compensation-related costs [13]. Future Outlook - The Zacks Consensus Estimate for fiscal 2026 earnings per share has increased by 3 cents to $7.64, with second-quarter revenue estimates indicating a 13.5% improvement year-over-year [14].

Nearly 70% say reducing manual processes is a key priority for working with sites About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholder ...

Company Performance - Veeva Systems (VEEV) closed at $279.76, down 1.02% from the previous trading session, underperforming the S&P 500 which lost 0.08% [1] - Over the last month, VEEV shares decreased by 0.6%, outperforming the Medical sector's loss of 3.99% but lagging behind the S&P 500's gain of 1.21% [2] Upcoming Earnings - Veeva Systems is set to release its earnings report on August 27, 2025, with an expected EPS of $1.9, reflecting a 17.28% growth year-over-year [3] - The Zacks Consensus Estimate for revenue is projected at $767.61 million, indicating a 13.52% increase from the previous year [3] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of $7.64 per share and revenue of $3.1 billion, representing year-over-year changes of +15.76% and +12.78%, respectively [4] - Recent changes in analyst estimates for Veeva Systems may indicate shifting business trends, with positive revisions suggesting analyst optimism [4] Valuation Metrics - Veeva Systems has a Forward P/E ratio of 36.98, which is a premium compared to the industry average of 23.67 [7] - The company has a PEG ratio of 1.59, while the industry average PEG ratio is 2.66 [7] Industry Ranking - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 91, placing it in the top 37% of over 250 industries [8] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [8]

Core Viewpoint - Veeva Systems (VEEV) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Business Improvement Indicators - The increase in earnings estimates and the Zacks rating upgrade for Veeva suggest an improvement in the company's underlying business, which could lead to higher stock prices [4][9]. - For the fiscal year ending January 2026, Veeva is expected to earn $7.64 per share, with a 4.1% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6][8]. - The upgrade of Veeva to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].